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Background: Little is known about prosthesis-patient mismatch (PPM) after transcatheter valve replacement (TAVR).
methods: The PARTNER trial Cohort A randomized patients 1:1 to TAVR or bioprosthetic SAVR. Postop PPM was defined as absent if indexed 
effective orifice area >0.85, moderate 0.65- 0.85, severe <0.65 cm2/m2. Mortality and rehospitalization (M/H) at 1 year were analyzed using the 
randomized (RCT) SAVR (n=270) and TAVR (n= 304) cohorts + the non-randomized continued access (NRCA, n=1637) cohort for TAVR.
results: PPM was lower in TAVR (overall: 44%; moderate: 30%; severe: 14 %) than SAVR (overall: 60%; moderate: 32%; severe: 28%; p<0.0001). 
In SAVR, baseline characteristics in PPM and no PPM were similar; in TAVR, PPM patients were younger and had larger BMI, more diabetes, more 
arrhythmia compared to no PPM. In SAVR, PPM patients had higher 1 yr mortality (HR: 3.8, 95%CI [1.4-10.1], p=0.007) and M/H (HR: 2.7 [1.4-5.2], 
p=0.003) than no PPM (Figure). Severe PPM had a 3.2 (p=0.002) and moderate PPM a 2.4 (p=0.02) fold increase in M/H. PPM had a multivariate 
2.8x increased mortality (p=0.08) and 2.6x increase in M/H (p=0.01). TAVR patients with and without PPM had similar 1 year multivariate mortality 
and M/H (Figure) in RCT, NRCA, or both.
conclusions: PPM is markedly reduced after TAVR compared to SAVR. In high risk severe AS, PPM has worse outcomes in SAVR but has no effect on 
M/H post TAVR. TAVR may be preferable to SAVR in patients susceptible to PPM, to reduce postop death and rehospitalization.
